Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development

  • Castillo, Sonia
  • Hontecillas-Prieto, Lourdes
  • Blanco-Gómez, Adrián
  • Sáez-Freire, María del Mar
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Pérez-Andrés, Martin
  • Orfao, Alberto
  • Cañamero, Marta
  • Mao, Jian-Hua
  • Gridley, Thomas
  • Castellanos-Martín, Andrés
  • Pérez-Losada, J.
PMCID: PMC4560637, Breast cancer is a major cause of mortality in women. The transcription factor SNAI2 has been implicated in the pathogenesis of several types of cancer, including breast cancer of basal origin. Here we show that SNAI2 is also important in the development of breast cancer of luminal origin in MMTV-ErbB2 mice. SNAI2 deficiency leads to longer latency and fewer luminal tumors, both of these being characteristics of pretumoral origin. These effects were associated with reduced proliferation and a decreased ability to generate mammospheres in normal mammary glands. However, the capacity to metastasize was not modified. Under conditions of increased ERBB2 oncogenic activity after pregnancy plus SNAI2 deficiency, both pretumoral defects - latency and tumor load - were compensated. However, the incidence of lung metastases was dramatically reduced. Furthermore, SNAI2 was required for proper postlactational involution of the breast. At 3 days post lactational involution, the mammary glands of Snai2-deficient mice exhibited lower levels of pSTAT3 and higher levels of pAKT1, resulting in decreased apoptosis. Abundant noninvoluted ducts were still present at 30 days post lactation, with a greater number of residual ERBB2+ cells. These results suggest that this defect in involution leads to an increase in the number of susceptible target cells for transformation, to the recovery of the capacity to generate mammospheres and to an increase in the number of tumors. Our work demonstrates the participation of SNAI2 in the pathogenesis of luminal breast cancer, and reveals an unexpected connection between the processes of postlactational involution and breast tumorigenesis in Snai2-null mutant mice., JPL was partially supported by FEDER and MICINN (PLE2009-119, SAF2014-56989-R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13), the “Fundación Eugenio Rodríguez Pascual”, the “Fundación Inbiomed” (Instituto Oncológico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa), and the “Fundación Sandra Ibarra de Solidaridad frente al Cáncer”. AC was supported by FIS (PI07/0057) and MICINN (PLE2009-119). SCLL was funded by a JAEdoc Fellowship (CSIC)/FSE. MMSF and ABG are funded by fellowships from the Junta de Castilla y Leon. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02-05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients

  • Mao, Jian-Hua
  • Diest, Paul J. van
  • Pérez-Losada, J.
  • Snijders, Antoine M.
Adjuvant radiotherapy (RT) in breast cancer (BC) is often used to eradicate remaining tumor cells following surgery with the goal of maximizing local control and increasing overall survival. The current study investigated the impact of age and BC molecular subtype on overall survival after RT using a meta-analysis of the METABRIC and TCGA BC patient cohorts. We found that RT significantly prolonged survival across the whole BC patient population. The survival benefit of RT was predominantly observed in stage II BC patients treated with breast conserving surgery. Patients were then stratified by age and molecular subtype to investigate survival rate associated with RT. An increase in survival for the luminal-A and basal BC molecular subtypes was observed after RT. Stratifying patients based on age revealed that increased survival was restricted to younger patients (≤60 years of age at diagnosis). There was a significant survival benefit of radiotherapy for younger patients with tumors of the luminal A and basal molecular subtypes. Patients with other breast tumor subtypes or older breast cancer patients did not seem to benefit effects of RT. Therefore, alternate local treatment strategies should be considered for older, luminal B, and HER2 driven BC patients., A.M.S. and J.H.M were supported by Lawrence Berkeley National Laboratory Directed Research and Development (LDRD) program funding under contract DE AC02-05CH11231. J.P.L. laboratory is partially funded by FEDER and MICINN (SAF2014-56989-R), Instituto de Salud Carlos III (PIE14/00066), Junta de Castilla y León (CSI001416), IBSAL (IBY15/00003)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma

  • Cañueto, Javier
  • Cardeñoso-Álvarez, Ester
  • García, Juan L.
  • Santos-Briz, Ángel
  • Castellanos-Martín, Andrés
  • Fernández-López, Emilia
  • Blanco-Gómez, Adrián
  • Pérez-Losada, J.
  • Román-Curto, Concépción
[Background]: Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans after basal cell carcinoma, and its incidence is dramatically rising. CSCC is rarely problematic, but given its high frequency, the absolute number of complicated cases is also high. It is necessary to identify molecular markers in order to recognize those CSCCs with poor prognosis. There is controversy concerning the role of epidermal growth factor receptor (EGFR) as a marker of prognosis in CSCC. In addition, EGFR-targeted therapies have emerged in recent years and a better understanding of the role of EGFR in CSCC may be of help for some patients in predicting prognosis and guiding curative management. [Objectives]: To evaluate the role of EGFR as a prognostic factor in CSCC. [Methods]: We evaluated clinical and histopathological features, including events of poor clinical evolution, in a series of 94 cases of CSCC. We also analysed EGFR expression by immunohistochemistry, fluorescent in situ hybridization and quantitative polymerase chain reaction. [Results]: We detected EGFR in 85 cases (90%), with overexpression in 33 cases (35%), and aberrant EGFR expression in the cytoplasm in 50 cases (53%). EGFR overexpression in the primary tumours was associated with lymph node progression, tumour–nodes–metastasis stage progression and proliferation (Ki-67 staining) in CSCC. EGFR overexpression and poor grade of differentiation were the strongest independent variables defining lymph node metastasis and progression in CSCC in a logistic regression model. [Conclusions]: We demonstrate that EGFR overexpression has prognostic implications associated with lymph node metastasis and progression in CSCC., J.P.‐L. was partially supported by FEDER and MICINN (PLE2009‐119, SAF2014‐56989‐R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y León (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13, BIO/SA31/15), IBSAL (IBY15/00003), the ‘Eugenio Rodríguez Pascual’, the ‘Fundación Inbiomed’ (Instituto Oncológico Obra Social de la Caja Guipozcoa‐San Sebastian, Kutxa) and the ‘Fundación Sandra Ibarra de Solidaridad frente al Cáncer’. C.R.‐C. is funded by Q3718001E (2009‐2010) and GRS 612/A/11 (2011‐2012) and ‘the Fundación Eugenio Rodríguez Pascual’. A.C.‐M. was supported by FIS (PI07/0057) and MICINN (PLE2009‐119)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The incidence of breast cancer increases with age until menopause, and breast cancer is more aggressive in younger women. The existence of epidemiological links between breast cancer and aging indicates that both processes share some common mechanisms of development. Oxidative stress is associated with both cancer susceptibility and aging. Here we observed that ERBB2-positive breast cancer, which developed in genetically heterogeneous ERBB2-positive transgenic mice generated by a backcross, is more aggressive in chronologically younger than in older mice (differentiated by the median survival of the cohort that was 79 weeks), similar to what occurs in humans. In this cohort, we estimated the oxidative biological age using a mathematical model that integrated several subphenotypes directly or indirectly related to oxidative stress. The model selected the serum levels of HDL-cholesterol and magnesium and total AKT1 and glutathione concentrations in the liver. The grade of aging was calculated as the difference between the predicted biological age and the chronological age. This comparison permitted the identification of biologically younger and older mice compared with their chronological age. Interestingly, biologically older mice developed more aggressive breast cancer than the biologically younger mice. Genomic regions on chromosomes 2 and 15 linked to the grade of oxidative aging were identified. The levels of expression of Zbp1 located on chromosome 2, a gene related to necroptosis and inflammation, positively correlated with the grade of aging and tumour aggressiveness. Moreover, the pattern of gene expression of genes linked to the inflammation and the response to infection pathways was enriched in the livers of biologically old mice. This study shows part of the complex interactions between breast cancer and aging., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R and SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation >de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02-05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Supplementary data for the biological age linked to oxidative stress modifies breast cancer aggressiveness

  • Sáez-Freire, María del Mar
  • Blanco-Gómez, Adrián
  • Castillo, Sonia
  • Gómez-Vecino, Aurora
  • Galvis-Jiménez, Julie Milena
  • Martín-Seisdedos, Carmen
  • Isidoro-García, María
  • Hontecillas-Prieto, Lourdes
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Mao, Jian-Hua
  • Prieto, Carlos
  • Castellanos-Martín, Andrés
  • Kaderali, Lars
  • Pérez-Losada, J.
The data presented in this article are related to the research paper entitled “The biological age linked to oxidative stress modifies breast cancer aggressiveness” (M.M. Sáez-Freire, A. Blanco-Gómez, S. Castillo-Lluva, A. Gómez-Vecino, J.M. Galvis-Jiménez, C. Martín-Seisdedos, M. Isidoro-García, L. Hontecillas-Prieto, M.B. García-Cenador, F.J. García-Criado, M.C. Patino-Alonso, P. Galindo-Villardón, J.H. Mao, C. Prieto, A. Castellanos-Martín, L. Kaderali, J. Pérez-Losada). The data shown were obtained from a population of transgenic mice, MMTV-Erbb2/Neu, with different susceptibility to breast cancer and a mixed genetic background generated by backcrossing. It was observed that the aggressiveness of breast cancer negatively correlates with age, being lower in chronologically old mice, similar to what occurs in humans. Given that oxidative stress is associated with tumour susceptibility and the degree of aging, the association between the aggressiveness of breast cancer and multiple intermediate phenotypes directly or indirectly related to oxidative stress was studied. Using a mathematical model, we defined biological age and the degree of aging as the difference between biological and chronological ages. As a result, we observed that biologically old mice predominated among those that developed the disease early on, that is, those that were chronologically young. We then identified the specific and common genetic components of Quantitative Trait loci or QTL associated with different evolution of breast cancer, the intermediate phenotypes related to oxidative stress studied, the biological age and the degree of aging. Lastly, we showed that the expression pattern in the livers of biologically old mice were enriched in signalling pathways related to inflammation and response to infections; whereas the biologically young mice exhibited enriched pathways related to mitochondrial activity. For the explanation and discussion of these data refer to the research article cited above., JPL was partially supported by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), the Instituto de Salud Carlos III (PIE14/00066), >Proyectos Integrados IBSAL 2015> (IBY15/00003), the Sandra Ibarra Foundation>de Solidaridad Frente al Cáncer> Foundation and >We can be heroes> Foundation. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological & Environmental Research, US Department of Energy (DE-AC02−05CH11231)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice.

  • Cañueto, Javier
  • Burguillo, Javier
  • Moyano-Bueno, David
  • Viñolas-Cuadros, Alex
  • Conde-Ferreirós, Alberto
  • Corchete, Luis A.
  • Pérez-Losada, J.
  • Román-Curto, Concépción
  • Román-Curto, Concépción
[Background]: The new eighth edition of the American Joint Committee on Cancer staging system (AJCC-8) incorporates changes regarding cutaneous squamous cell carcinoma (CSCC)., [Objectives]: We aimed to compare the AJCC-8 staging system with the previous seventh edition of the AJCC staging system (AJCC-7) and the Brigham and Women's Hospital (BWH) alternative staging system to identify their usefulness and the utility of their risk factors in defining prognostic groups in CSCC., [Methods]: A series of 186 CSCCs of the head and neck were retrospectively collected. All 3 staging systems were compared from the standpoint of their ability to predict poor prognosis. Binary logistic regression models were built to determine which risk factors were most relevant., [Results]: Poor prognosis was mainly associated with stage T2 of the AJCC-7, with stages T2b/T3 of the BWH system, and with stage T3 of the AJCC-8. The AJCC-8 and the BWH staging systems displayed overlap with each another in predicting poor prognosis, and both were superior to the AJCC-7. The new risk factors incorporated into the AJCC-8 and the poor degree of differentiation were independently associated with poor outcome., Dr Cañueto is partially supported by a grant (GRS 1342/A/16) from the Regional Health Office of Castile and Leon and by the program INT/M/16/17 from the Regional Health Office of Castile and Leon. Dr Pérez-Losada was partially supported by FEDER and the MICINN (grants SAF2014-56989-R and SAF2017-88854-R), the Instituto de Salud Carlos III (PIE14/00066), and the We Can Be Heroes Foundation
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression

  • Blanco-Gómez, Adrián
  • Hontecillas-Prieto, Lourdes
  • Corchado Cobos, Roberto
  • García-Sancha, Natalia
  • Salvador, Nélida
  • Castellanos-Martín, Andrés
  • Sáez-Freire, María del Mar
  • Mendiburu-Eliçabe, Marina
  • Alonso-López, D.
  • Rivas, Javier de las
  • Lorente, Mar
  • García-Casas, Ana
  • Carmen, Sofía del
  • Abad-Hernández, María del Mar
  • Cruz, Juan Jesús
  • Rodríguez-Sánchez, César Augusto
  • Claros-Ampuero, Juncal
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Orimo, Akira
  • Gridley, Thomas
  • Pérez-Losada, J.
  • Castillo, Sonia
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2+/ERBB2+ breast cancers in which SNAI2 expression in the stroma but not the epithelium correlates with tumor proliferation. To determine how stromal SNAI2 might influence HER2+ tumor behavior, Snai2-deficient mice were crossed with a mouse line carrying the ErbB2/Neu protooncogene to generate HER2+/ERBB2+ breast cancer. Tumors generated in this model expressed SNAI2 in the stroma but not the epithelium, allowing for the role of stromal SNAI2 to be studied without interference from the epithelial compartment. The absence of SNAI2 in the stroma of HER2+/ERBB2+ tumors is associated with: (i) lower levels of cyclin D1 (CCND1) and reduced tumor epithelium proliferation; (ii) higher levels of AKT and a lower incidence of metastasis; (iii) lower levels of angiopoietin-2 (ANGPT2), and more necrosis. Together, these results indicate that the loss of SNAI2 in cancer-associated fibroblasts limits the production of some cytokines, which influences AKT/ERK tumor signaling and subsequent proliferative and metastatic capacity of ERBB2+ breast cancer cells. Accordingly, SNAI2 expression in the stroma enhanced the tumorigenicity of luminal B HER2+/ERBB2+ breast cancers. This work emphasizes the importance of stromal SNAI2 in breast cancer progression and patients' prognosis., S. Castillo-Lluva was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness (Ministerio de Economía y Competitividad; MINECO), and the work was supported by a MINECO/FEDER research grant (SAF2015-64499-R; RTI2018-094130-B-100). N. García-Sancha was partially supported by the RTI2018-094130-B-100 budget. J. Pérez-Losada was partially supported by FEDER funds, the Carlos III Health Institute (PIE14/00066), MINECO (SAF2014-56989-R, SAF2017-88854R), Castile and León (CSI234P18), the Sandra Ibarra Foundation for Solidarity against Cancer and the “We can be heroes” Foundation. N. García-Sancha is a recipient of an FPU fellowship (MINECO/FEDER). R. Corchado-Cobos, M.d.M. Sáez-Freire, and A. Blanco-Gómez were funded by fellowships from the Spanish Regional Government of Castile and León. The development of the Snai2 KO mice was supported by NIH grant R01HD034883 (to T. Gridley)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy

  • Xiao, Yi
  • Yin, Chunli
  • Wang, Yuli
  • Lv, Hanlin
  • Wang, Wenqing
  • Huang, Yurong
  • Pérez-Losada, J.
  • Snijders, Antoine M.
  • Mao, Jian-Hua
  • Zhang, Pengju
© 2018 The Authors., Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), is an effective treatment for non-small-cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance. The tumor suppressor gene FBXW7 modulates chemosensitivity in various human cancers. However, its role in EGFR-TKI therapy in NSCLC has not been well studied. Here, we demonstrate that the mice with deficient Fbxw7 have greater susceptibility to urethane-induced lung tumor development. Through analysis of The Cancer Genome Atlas data, we show that deletion of FBXW7 occurs in 30.9% of lung adenocarcinomas and 63.5% of lung squamous cell carcinomas, which significantly leads to decrease in FBXW7 mRNA expression. The reduction in FBXW7 mRNA level is associated with poor overall survival in lung cancer patients. FBXW7 knockdown dramatically promotes epithelial–mesenchymal transition, migration, and invasion in NSCLC cells. Moreover, with silenced FBXW7, EGFR-TKI-sensitive cells become resistant to gefitinib, which is reversed by the mammalian target of rapamycin inhibitor, rapamycin. Furthermore, xenograft mouse model studies show that FBXW7 knockdown enhances tumorigenesis and resistance to gefitinib. Combination of gefitinib with rapamycin treatment suppresses tumor formation of gefitinib-resistant (GR) FBXW7-knockdown cells. In conclusion, our findings suggest that loss of FBXW7 promotes NSCLC progression as well as gefitinib resistance and combination of gefitinib and rapamycin may provide an effective therapy for GR NSCLC., This work was supported by National Natural Science Foundation of China (Nos 81672858, 81470127); by the Natural Science Foundation of Shandong province (No. ZR2014HM032) (to PZ), and Lawrence Berkeley National Laboratory Directed Research and Development (LDRD) program funding under contract DE AC02-05CH11231 (to AMS and JHM); and by FEDER and the MICINN (SAF2014-56989-R, SAF2017-88854R), and the Instituto de Salud Carlos III (PIE14/00066) and ‘We can be heroes’ Foundation (to JPL)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Rapid growth rate is associated with poor prognosis in cutaneous squamous cell carcinoma

  • Cañueto, Javier
  • Martin-Vallejo, Javier
  • Cardeñoso-Álvarez, Ester
  • Fernández-López, Emilia
  • Pérez-Losada, J.
  • Román-Curto, Concépción
[Background]: Cutaneous squamous cell carcinoma (cSCC) represents the most common form of skin cancer after basal cell carcinoma, and can be both locally invasive and metastatic to distant sites. Growth rate (GR) has been poorly evaluated in cSCC, despite clinical evidence suggesting that GR is an important risk factor in cSCC., [Aim]: To analyse the influence of GR in cSCC prognosis., [Methods]: We retrospectively evaluated GR in a series of 90 cSCCs and tried to correlate GR with prognosis in cSCC., [Results]: We demonstrated that tumours with a GR of > 4 mm/month exhibit a higher risk of nodal progression and a shorter progression time to lymph node metastasis in cSCC than those with GR of < 4 mm/month. As expected, GR correlated with tumour proliferation, as determined by Ki-67 expression., [Conclusions]: We consider a GR of 4 mm/month as the cutoff point that distinguishes between rapid- and slow-progressing tumours and, more importantly, to identify a subset of high-risk cSCCs., JC was partially supported by Gerencia Regional de Salud, Junta de Castilla y León (GRS 1342/A/16) and by the programme INT/M/16/17. JPL was partially supported by FEDER and MICINN (SAF2014–56989-R), Instituto de Salud Carlos III (PIE14/00066), Junta de Castilla y León (BIO/SA31/15, CSI001416), IBSAL (IBY15/00003), the Eugenio Rodríguez Pascual, the Fundación Sandra Ibarra de Solidaridad frente al Cáncer and We can be Heroes Foundation. CR-C is funded by Q3718001E (2009–2010) and GRS 612/A/11 (2011–2012) and the Fundación Eugenio Rodríguez Pascual.